Abstract: The present invention provides a phospholipase D having an amino acid sequence as shown in SEQ ID NO. 1, and further provides a gene sequence encoding phospholipase D, which has a nucleotide sequence as shown in SEQ ID NO. 2. The present invention also provides a method for improving the expression level of phospholipase D by systematically engineering the expression elements. The method comprises screening and replacement of signal peptides, ribosome binding sites and promoters. The constructed recombinant plasmid is transformed into a host cell, and the recombinant strain is capable of successfully expressing phospholipase D. The phospholipase D of the present invention has a good phosphatidyl transferring ability, and can be used for synthesizing the product phosphatidylserine with lecithin and L-serine as substrates. The recombinant strain has good stability of enzyme activity and short fermentation period, which lays the foundation for large-scale industrial production.

Abstract: The present disclosure provides RNA-guided CRISPR-Cas effector proteins, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided CRISPR-Cas effector protein of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA. The present disclosure provides methods of modulating transcription of a target nucleic acid.

Abstract: The present invention aims to provide a modified Cas9 protein with relaxed restriction on target sequence while maintaining binding ability to guide RNA, and use thereof. A protein containing the amino acid sequence of SEQ ID NO: 1 in which the 1335-position arginine is mutated into alanine (R1335A), isoleucine (R1335I), methionine (R1335M), threonine (R1335T) or valine (R1335V), the 1111-position leucine is mutated into arginine (L1111R), the 1135-position aspartic acid is mutated into valine (D1135V), the 1218-position glycine is mutated into arginine (G1218R), the 1219-position glutamic acid is mutated into phenylalanine (E1219F), the 1322-position alanine is mutated into arginine (A1322R), and the 1337-position threonine is mutated into arginine (T1337R), and the like.

Abstract: The present invention relates to a method for preparing an adipate ester or thioester. The invention further relates to a method for preparing adipic acid from said ester or thioester. Further the invention provides a number of methods for preparing an intermediate for said ester or thioester. Further the invention relates to a method for preparing 6-amino caproic acid (6-ACA), a method for preparing 5-formyl valeric acid (5-FVA), and a method for preparing caprolactam. Further, the invention relates to a host cell for use in a method according to the invention.

Abstract: Provided herein are glucose and galactose biosensors and methods of making and using the same.

Abstract: The present disclosure relates to consortia of bacteria strains and composition comprising one or more bacterial strains disclosed herein. These consortia of isolated bacteria cultures and compositions comprising said cultures, having greater activity than would be observed for the individual bacteria cultures and compositions. A composition of the disclosure may advantageously be used for enhancing the availability of soil phosphorus and other macronutrients and/or micronutrients to plants, and thereby enhancing their growth and yield.

Abstract: The present disclosure relates to a novel acetohydroxy acid synthase, a microorganism comprising the same, or a method for producing an L-branched-chain amino acid using the same.

Abstract: Described herein are variants of acetylserotonin O-methyltransferase (ASMT) as well as vectors and recombinant microbial host cells expressing such ASMT variant and their use in producing melatonin and related compounds. Preferred ASMT variants provide for a higher turnover of N-acetylserotonin into melatonin.

Abstract: The present invention relates to lipase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

Abstract: The present invention provides a method of producing astaxanthin and lysine in recombinant gram-positive bacteria comprising a nucleic acid sequence encoding for a crtZ-protein from F. pelagi and comprises a nucleic acid sequence encoding for a crtW-protein.

Abstract: The present disclosure relates to methods for producing recombinant proteins, as well as compositions used in and produced by such methods. Specifically, the present disclosure relates to methods for producing high secreted yields of recombinant proteins, and the compositions provided herein include expression constructs, recombinant vectors, and recombinant host cells that comprise polynucleotide sequences encoding proteins operably linked to recombinant secretion signals that comprise the leader peptide of the ?-mating factor (?MF) of Saccharomyces cerevisiae and a non-?MF signal peptide.

Abstract: The present disclosure relates to a microorganism for producing an L-amino acid with enhanced activity of ?-glucosidase and a method for producing an L-amino acid using the same. According to the present disclosure, the microorganism of the genus Corynebacterium producing an L-amino acid has enhanced activity of ?-glucosidase, thereby improving L-amino acid production yield. Therefore, the microorganism may be very usefully used for L-amino acid production.

Abstract: Provided is a method of producing one or more sesquiterpene compounds comprising: contacting an acyclic FPP precursor with a polypeptide having terpene synthase activity, wherein the polypeptide comprises an amino acid sequence that has at least 55% sequence identity to SEQ ID NO: 1, to produce one or more terpenes selected from the group consisting of isovalencene, spirovetiva-1(10),7(11)-diene and valencene or derivatives thereof, or mixture of sesquiterpenes comprising one or more of isovalencene, spirovetiva-1(10),7(11)-diene and/or valencene; and optionally isolating the one or more terpenes or the mixture.

Abstract: The disclosure relates to a tyrosol-producing recombinant Escherichia coli and a construction method and application thereof and belongs to the technical field of bioengineering. The Escherichia coli undergoes heterologous expression of a codon-optimized Saccharomyces cerevisiae pyruvate decarboxylase gene ARO10*. According to the recombinant Escherichia coli, five sites of a lacI site, a trpE site, a pabB site, a pabA site and a pykF site of an Escherichia coli genome are deleted, and at the same time, the ARO10* gene is integrated at each site of the five sites to obtain a strain containing multiple copies of the ARO10* gene. On the basis of the above recombinant strain, the ARO10* gene is randomly integrated at multiple sites, and it is found that a strain with high-yield production of tyrosol can be obtained by inserting the ARO10* gene at a yccX site. Fermentation using this strain does not require inducers or antibiotics. After fermentation is carried out for 48 hours, the yield of tyrosol can reach 32.

Abstract: Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human T cell receptor alpha constant region gene. The present disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells.

Abstract: A microbiological process for the preparation of amides from the corresponding nitriles by enzymatic hydrolysis with nitrile hydratase enzyme from a bacterial strain of Rhodococcus biphenylivorans species is described.

Abstract: The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide.

Abstract: Genetically modified LeuCD? enzyme complexes, processes for preparing a C7-C11 2-ketoacid utilizing genetically modified LeuCD? enzyme complexes, and microbial organisms including modified LeuCD enzyme complexes are described. The instantly-disclosed genetically modified LeuCD? enzyme complexes, processes for preparing a C7-C11 2-ketoacid, and microbial organisms including modified LeuCD? enzyme complexes can be particularly useful for producing C6-C10 aldehydes, alkanes, alcohols, and carboxylic acids, both in vivo and in vitro.

Abstract: Disclosed herein are enzymatically active Cas9 (eaCas9) fusion molecules, comprising an eaCas9 molecule linked, e.g., covalently or non-covalently, to a template nucleic acid; gene editing systems comprising the eaCas9 fusion molecules, and methods of use thereof.

Abstract: The present disclosure provides DNA-guided CRISPR systems; polynucleotides comprising DNA, RNA and mixtures thereof for use with CRISPR systems; and methods of use involving such polynucleotides and DNA-guided CRISPR systems.